.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,393,372

« Back to Dashboard

Claims for Patent: 9,393,372

Title:Dry powder drug delivery system
Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation.
Inventor(s): Smutney; Chad C. (Watertown, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), Kinsey; P. Spencer (Sandy Hook, CT), Overfield; Dennis (Fairfield, CT), Sahi; Carl R. (Coventry, CT), Billings; Christine (Danbury, CT), Marino; Mark T. (Danbury, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:13/933,845
Patent Claims: 1. An inhalation system, comprising: a dry powder inhaler comprising: a mouthpiece and a container, wherein the container comprises a top and a bottom which are moveable relative to one another by a translational motion to create a first flow path, wherein 20% to 70% of total airflow through the inhaler enters and exits the container, and wherein the container includes a dry powder formulation comprising diketopiperazine particles; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein the second flow path converges with the first flow path at a substantially perpendicular angle, and wherein after a single inhalation from the inhalation system, diketopiperazine in a subject's plasma has an AUC.sub.0-.infin. greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.

2. The inhalation system of claim 1, wherein the container is removable from the dry powder inhaler.

3. The inhalation system of claim 1, wherein the container is reconfigurable in the dry powder inhaler from a containment configuration to a dosing configuration.

4. The inhalation system of claim 1, wherein the dry powder inhaler is a breath powered inhaler.

5. The inhalation system of claim 1, wherein the diketopiperazine particles include ##STR00003##

6. The inhalation system of claim 1, wherein the diketopiperazine has a T.sub.max of less than 1 hour.

7. The inhalation system of claim 1, wherein the dry powder formulation includes an active ingredient.

8. The inhalation system of claim 7, wherein the active ingredient is a peptide, polypeptide, protein, or a combination thereof.

9. The inhalation system of claim 7, wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, and argatroban, anti-SSX-2.sub.41-49, anti-NY-ES0-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

10. The inhalation system of claim 7, wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, analogs thereof, or a combination thereof.

11. The inhalation system of claim 7, wherein the active ingredient is insulin.

12. The inhalation system of claim 7, wherein the active ingredient is glucagon-like peptide 1.

13. The inhalation system of claim 7, wherein the active ingredient is oxyntomodulin.

14. The inhalation system of claim 1, wherein the inhalation system is operably configured to emit a powder plume comprising the diketopiperazine particles having a volumetric median geometric diameter ranging from 2 .mu.m to 8 .mu.m and a geometric standard deviation of less than 4 .mu.m.

15. The inhalation system of claim 1, wherein the inhalation system is operably configured to emit more than 90% of the dry powder formulation and the diketopiperazine particles dissolve and are absorbed into the blood in less than 30 minutes yielding a peak concentration of the diketopiperazine after the single inhalation.

16. The inhalation system of claim 11, wherein the inhalation system is configured to deliver insulin to the pulmonary circulation of the subject, and the insulin measured at an exposure having a AUC.sub.0-2 hr greater than 160 .mu.U*min/mL per unit of insulin emitted in the dry powder formulation.

17. The inhalation system of claim 16, wherein an insulin C.sub.max is achieved less than 30 minutes after administration.

18. The inhalation system of claim 1, wherein the first flow path is sheared by the second flow path when the first flow path exits the container.

19. An inhalation system, comprising: a dry powder inhaler comprising: a mouthpiece and a container, wherein the container includes a dry powder formulation comprising diketopiperazine particles; a first flow path wherein 20% to 70% of total airflow through the inhaler enters and exits the container; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein the first flow path exits the container substantially perpendicularly to the second flow path and is sheared by the second flow path; and wherein after a single inhalation from the inhalation system, diketopiperazine in a subject's plasma has an AUC.sub.0-.infin. greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.

20. An inhalation system, comprising: a dry powder inhaler comprising: a mouthpiece and a container, wherein the container comprises a top and a bottom which are moveable relative to one another by a translational motion, wherein the container includes a dry powder formulation comprising diketopiperazine particles, and wherein the container does not include an air conduit resulting from puncturing or peeling; a first flow path wherein 20% to 70% of total airflow through the inhaler enters and exits the container; and a second flow path wherein 30-80% of total airflow through the inhaler by-passes the container; wherein after a single inhalation from the inhalation system, diketopiperazine in a subject's plasma has an AUC.sub.0-.infin. greater than 2,300 ng*min/mL per mg of the diketopiperazine content in the dry powder formulation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc